EyePoint, Inc.

What they do

EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. Its lead candidate, DURAVYU, combines vorolanib with its proprietary bioerodible Durasert E technology for sustained intraocular delivery. DURAVYU is in Phase 3 trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company also has a commercial manufacturing facility in Northbridge, Massachusetts and is developing EYP-2301 (razuprotafib), a TIE-2 agonist.

Revenue drivers

• License and collaboration agreements (e.g., Ocumension) — The company has a manufacturing agreement to supply YUTIQ and DEXYCU to Ocumension, which contributes revenue, though reported revenue has declined sharply in recent quarters.
• Product sales (YUTIQ, DEXYCU, ILUVIEN royalties) — ILUVIEN and YUTIQ royalties were a prior revenue source, but the royalty obligation was bought out in March 2025, terminating the related revenue stream.
• No approved products for DURAVYU — DURAVYU is not yet approved; current revenue does not include any sales from this candidate.

Recent performance

For the fiscal year ended December 31, 2025, EyePoint reported revenue of $31.4 million, down from $43.3 million in 2024, and a net loss of $232.0 million, compared to a net loss of $130.9 million in 2024. Quarterly revenue has declined from $966,000 in Q3 2025 to $507,000 in Q2 2026. As of June 30, 2026, the company had $110.5 million in cash and equivalents and total assets of $228.2 million.

Strategy

EyePoint is prioritizing the clinical development of DURAVYU, with Phase 3 wet AMD trials (LUGANO and LUCIA) fully enrolled and topline data expected in August and Q4 2026, respectively. The company is also enrolling patients in global Phase 3 DME trials (COMO and CAPRI), with topline data anticipated in Q4 2027. It is leveraging a proprietary bioerodible Durasert E technology for sustained drug delivery, aiming to differentiate DURAVYU through its multi-mechanism of action (VEGF, PDGF, and IL-6/JAK1 inhibition). Management expects to fund operations into Q4 2027 with $180.5 million in cash and investments as of June 30, 2026.

Risks

• Clinical trial failure risk — DURAVYU is in Phase 3; if trials fail to meet endpoints, the company's lead candidate may not gain approval.
• Capital needs — The company has incurred significant losses and may need additional capital to fund operations, which could be dilutive.
• FDA regulatory and inspection issues — A July 2024 FDA Warning Letter regarding YUTIQ manufacturing and a DOJ investigation could lead to enforcement actions or operational constraints.
• Competition and market adoption — Even if approved, DURAVYU may face competition from existing anti-VEGF therapies and could fail to achieve market acceptance.

Outlook

Management expects to report topline data from the LUGANO Phase 3 wet AMD trial in August 2026 and LUCIA topline data in Q4 2026. Enrollment in the Phase 3 DME program (COMO and CAPRI) is complete, with topline data expected in Q4 2027. The company believes its cash runway supports operations into Q4 2027, beyond the wet AMD topline data.